Search

Your search keyword '"Horvath, L.G."' showing total 19 results
Start Over Author "Horvath, L.G."
19 results on '"Horvath, L.G."'

3. 318MO Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)

Author

Tie, J., primary, Cohen, J., additional, Lahouel, K., additional, Lo, S.N., additional, Wang, Y., additional, Wong, R., additional, Shapiro, J., additional, Harris, S., additional, Khattak, A., additional, Burge, M., additional, Horvath, L.G., additional, Karapetis, C.S., additional, Shannon, J., additional, Singh, M., additional, Yip, D., additional, Papadopoulos, N., additional, Tomasetti, C., additional, Kinzler, K., additional, Vogelstein, B., additional, and Gibbs, P., additional

Published
2022
Full Text
View/download PDF

4. 1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention

Author

Scheinberg, T., primary, Fitzpatrick, M., additional, Lin, H-M., additional, Azad, A.A., additional, Bonnitcha, P., additional, Davies, A.G., additional, Heller, G., additional, Huynh, K., additional, Mak, B., additional, Mahon, K., additional, Meikle, P., additional, Sullivan, D., additional, and Horvath, L.G., additional

Published
2022
Full Text
View/download PDF

6. 635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer

Author

Lin, H-M., primary, Mak, B., additional, Huynh, K., additional, Kwan, E.M., additional, Fettke, H., additional, Tran, B., additional, Davis, I.D., additional, Mahon, K.L., additional, Stockler, M.R., additional, Briscoe, K., additional, Marx, G.M., additional, Du, P., additional, Yu, J., additional, Jia, S., additional, Joshua, A.M., additional, Azad, A.A., additional, Butler, L.M., additional, Meikle, P.J., additional, and Horvath, L.G., additional

Published
2021
Full Text
View/download PDF

7. 596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)

Author

Mak, B., primary, Lin, H-M., additional, Kwan, E.M., additional, Fettke, H., additional, Tran, B., additional, Davis, I.D., additional, Mahon, K.L., additional, Stockler, M.R., additional, Briscoe, K., additional, Marx, G.M., additional, Kohli, M., additional, Tan, W., additional, Huynh, K., additional, Du, P., additional, Yu, J., additional, Jia, S., additional, Joshua, A.M., additional, Azad, A.A., additional, Meikle, P.J., additional, and Horvath, L.G., additional

Published
2021
Full Text
View/download PDF

8. 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Author

Sandhu, S.K., primary, Joshua, A.M., additional, Emmett, L., additional, Spain, L., additional, Horvath, L.G., additional, Crumbaker, M., additional, Anton, A., additional, Wallace, R., additional, Pasam, A., additional, Bressel, M., additional, Cassidy, E., additional, Banks, P., additional, Kumar, A.R., additional, Alipour, R., additional, Akhurst, T., additional, Kong, G., additional, Davis, I.D., additional, Williams, S., additional, Hicks, R., additional, and Hofman, M., additional

Published
2021
Full Text
View/download PDF

10. 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

Author

Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., and Sweeney, C.

Published
2023
Full Text
View/download PDF

12. 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., Strickland, A.H., Briscoe, K., Varma, S., Barnet, M., Jackson, C., Horvath, L.G., Price, T.J., Tebbutt, N., Karki, B., Diakos, C.I., Chia, J., Toh, H.C., Jones, F.S., and Segelov, E.

Published
2023
Full Text
View/download PDF

13. Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

Author

Stockler, M.R., primary, Martin, A.J., additional, Dhillon, H., additional, Davis, I.D., additional, Chi, K.N., additional, Chowdhury, S., additional, Horvath, L.G., additional, Lawrence, N.J., additional, Marx, G.M., additional, Caffrey, J Mc, additional, McDermott, R., additional, North, S.A., additional, Parnis, F., additional, Pook, D.W., additional, Reaume, M.N., additional, Sandhu, S.K., additional, Tan, T.H., additional, Thomson, A., additional, Zielinski, R., additional, and Sweeney, C.J., additional

Published
2019
Full Text
View/download PDF

15. LBA53 - Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

Author

Stockler, M.R., Martin, A.J., Dhillon, H., Davis, I.D., Chi, K.N., Chowdhury, S., Horvath, L.G., Lawrence, N.J., Marx, G.M., Caffrey, J Mc, McDermott, R., North, S.A., Parnis, F., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, T.H., Thomson, A., Zielinski, R., and Sweeney, C.J.

Published
2019
Full Text
View/download PDF

18. Statins – No more cream for cancer.

Author

Horvath, L.G. and Gillessen, S.

Subjects
*LIPID metabolism, *CELL proliferation, *LIPIDS, *LOW density lipoproteins, *PROSTATE tumors, *PHARMACODYNAMICS, *STATINS (Cardiovascular agents)
Published
2019
Full Text
View/download PDF

19. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Kelly, W.K., Danila, D.C., Lin, C-C., Lee, J-L., Matsubara, N., Ward, P.J., Armstrong, A.J., Pook, D.W., Kim, M., Dorff, T., Fischer, S., Lin, Y-C., Horvath, L.G., Sumey, C., Yang, Z., Jurida, G., Connarn, J., Penny, H., Stieglmaier, J., and Appleman, L.J.

Subjects
*CASTRATION-resistant prostate cancer, *CD3 antigen
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results